Going concern and capital dependence
The company has no revenue and must raise additional capital to fund operations and trials.
- Scope
- Equity and debt financing, dilution, potential operational scaling back
- Materiality
- high
CytoDyn Inc.
CytoDyn Inc. is a clinical-stage biotechnology company focused on developing leronlimab (PRO 140), a humanized monoclonal antibody that targets CCR5. The company is pursuing the drug candidate across multiple therapeutic areas, with current emphasis on solid-tumor oncology, while also exploring a longer-acting modified therapeutic through a joint development effort.
0.26
0.37
| % | |
|---|---|
| Leronlimab clinical candidate | 100% Development of the company’s lead CCR5-targeting antibody for multiple therapeutic indications. |
| Long-acting therapeutic collaboration | 0% Joint development work aimed at creating a modified, longer-acting version of the molecule. |
| Clinical and pre-clinical development services | 0% Internal and outsourced R&D, testing, and regulatory work supporting the drug candidate. |
CytoDyn does not currently sell commercial products; its primary “customers” are future patients, physicians, and...
- Future patients in oncology and other indicationsprimary
Would receive leronlimab if approved; the company is developing the drug for solid-tumor oncology and other potential uses.
- Physicians and clinical opinion leadersprimary
Influence trial design, adoption, and eventual prescribing if the product reaches market.
- Regulatorsprimary
FDA and other agencies review safety, efficacy, manufacturing, and labeling before commercialization.
- Contract research and manufacturing partnerssecondary
Buy development work, trial execution, and manufacturing services to support the pipeline.
CytoDyn is headquartered in Vancouver, Washington and operates as a U.S.-based clinical-stage biotech...
- •Headquartered in Vancouver, Washington, United States
- •U.S. is the operating base for management and corporate functions
- •Patent filings may extend to Canada, China, Japan, and Europe
- •Clinical and manufacturing partners may be located outside the U.S.
- •No disclosed revenue geography because the company has no revenue
CytoDyn’s strategy is to advance leronlimab through additional clinical work, secure regulatory approval, and...
01
Complete clinical development of leronlimabshort-term
Approval depends on generating sufficient safety and efficacy data.
02
Secure external funding and partnershipsshort-term
The company is a going concern and needs capital to fund operations.
03
Develop a longer-acting CCR5 therapeuticmedium-term
A modified molecule could improve patient convenience and extend IP value.
CytoDyn is highly dependent on successful clinical outcomes, regulatory approval, and third-party execution, while...
Clinical development failure
Leronlimab is the core asset; weak efficacy or safety data would impair approval prospects.
- Scope
- Lead program, oncology pipeline
- Materiality
- high
Third-party manufacturing and CRO dependence
The company relies on external partners for trials, GMP supply, fill-finish, and packaging.
- Scope
- Clinical timelines, regulatory compliance, supply continuity
- Materiality
- high
Regulatory and legal proceedings
FDA/SEC oversight and litigation can divert management and increase costs.
- Scope
- Cash burn, reputation, stock price volatility
- Materiality
- high
Intellectual property protection
Value depends on maintaining patent coverage and defending ownership or infringement claims.
- Scope
- Leronlimab and future modified molecules
- Materiality
- medium
Going-concern assessment
Can affect audit opinion, disclosure tone, and investor perception
Stock-based compensation
Affects G&A and R&D expense trends
Convertible debt and warrant accounting
Can distort period-to-period comparability
R&D cost classification
Changes the mix between R&D and G&A without changing total cash burn
: 28.4.2026